Aurinia Pharmaceuticals Inc
Symbol: AUPH (NASDAQ)
11.68
▼ (-1.35%) -0.160
Company Description:
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Key Stats
- Today's Open: $11.85
- Today's High: $11.853
- Today's Low: $11.68
- Today's Volume: 1.05M
- Yesterday Close: $11.84
- Yesterday High: $11.855
- Yesterday Low: $11.63
- Yesterday Volume: 767.73K
- Last Min Volume: 30.57K
- Last Min High: $11.68
- Last Min Low: $11.68
- Last Min VWAP: $11.68
Company Profile
- Name: Aurinia Pharmaceuticals Inc
- Website: https://www.auriniapharma.com
- Listed Date: 2009-10-21
- Location: EDMONTON, A0
- Market Status: Active
- CIK Number: 0001600620
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.56B
- Round Lot: 100
- Outstanding Shares: 131.63M
- Asset Type: CS
RECENT FILINGS FOR AUPH
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-13 | SCHEDULE 13D/A | View |
| 2025-08-05 | 4 | View |
| 2025-08-05 | 4 | View |
| 2025-07-31 | 10-Q | View |
| 2025-07-31 | 8-K | View |
| 2025-06-30 | 8-K | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 4 | View |
| 2025-05-16 | 3 | View |
| 2025-05-16 | 3 | View |
| 2025-05-16 | S-8 | View |
| 2025-05-15 | 8-K | View |
| 2025-05-12 | 10-Q | View |
| 2025-05-12 | 8-K | View |
| 2025-04-30 | DEFA14A | View |
| 2025-04-29 | DEFA14A | View |
| 2025-04-17 | DEF 14A | View |
| 2025-03-07 | 4 | View |
Latest News on AUPH